Karyopharm Therapeutics Inc. Enters into Preferred Provider Agreement with Clinipace Worldwide
Technology-Amplified dCRO Model Accelerating Personalized Approach to Targeted Therapies, Including Greater Collaboration, Higher Data Quality, and Reduced Development Costs
Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases.
As part of a long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
“It is our mission to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture,” noted Sharon Shacham, Ph.D., MBA, Karyopharm’s Founder, President and Chief Scientific Officer. “By partnering with a like-minded technology-driven company like Clinipace, we believe we can help accelerate our first-in-class small molecule modulators into effective targeted therapeutics for life threatening conditions.”
“As tailored therapies such as those Karyopharm have under development become more prominent, drug developers must find increasingly innovative ways to help bring their products to market in the most effective and efficient manner,” said Jeff Williams, CEO and co-founder, Clinipace Worldwide. “Working with a technology-enabled digital CRO (dCRO) provides our clients with a significant level of information sharing that helps increase collaboration, improves data quality, and reduces their overall development costs.”
